Safety and Efficacy of Chloroquine Associated With Dehydroepiandrosterone Sulphate to Treat Uncomplicated Falciparum Malaria
Study Details
Study Description
Brief Summary
This study aims to evaluate the safety and efficacy of a standard chloroquine drug regimen administration supplemented with dehydroepiandrosterone sulfate against drug-resistant malaria.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Detailed Description
Worldwide progression of Plasmodium falciparum chloroquine (CQ), amodiaquine and sulfadoxine-pyrimethamine resistance leaves few alternative for the control of malaria, particularly in Africa. For some strains of P. falciparum and P. berghei, the resistance to CQ and AQ is linked to an increase in reduced glutathione (GSH) levels and GSH-related enzyme activity, such as glucose 6-phosphate deshydrogenase (G6PD). The pro-hormone dehydroepiandrosterone sulphate can be used to potentiate the antimalarial action of CQ on drug resistant P. falciparum strains, by inhibiting parasite G6PD activity. This hormone has a second advantage: it is metabolised in human into a series of potent immunomodulatory steroids which may be in the causal pathway that allowed the induction of protective immune responses against several infections, included malaria. This first study evaluated the tolerance and efficacy of a standard CQ regimen supplemented with dehydroepiandrosterone sulphate for the treatment of drug resistant uncomplicated falciparum malaria.
Study Design
Outcome Measures
Primary Outcome Measures
- Development of any adverse event; []
- Rate of clinical and/or parasitological failure during the 14 days of follow up. []
Secondary Outcome Measures
- Proportion of patients with positive blood smear during follow-u; []
- Mean parasitemia during follow-up; []
- Proportion of patients with clinical symptoms on day 3. []
Eligibility Criteria
Criteria
Inclusion Criteria:
-
signing an informed consent (informed consent was given by legal guardian for children);
-
age egal or more than 15 years;
-
fever (axillary temperature egal or more than 37.5 °C and less than 40°C) or a history of fever within the last 24 hours;
-
no sign suggestive of other febrile illness;
-
absence of signs of complicated malaria (WHO criteria);
-
willingness to participate in follow-up for 14 days
-
a positive thick blood film for P. falciparum without other detectable infectious microorganisms
Exclusion Criteria:
-
patients taking glucocorticoids or other immuno-suppressive drugs, or indicating recent antimalarial drug history (verbal questionnaire);
-
severe malaria;
-
mixed infections;
-
women using contraceptives;
-
pregnant women;
-
breast-feeding women.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Institute of Medical Research and study of Medicinal Plants, Medical Research Center | Yaounde | Cameroon |
Sponsors and Collaborators
- Université Victor Segalen Bordeaux 2
Investigators
- Study Director: Michel LE BRAS, Professor, Université Victor Segalen Bordeaux 2, Centre René Labusquière (Santé et Développement)
- Principal Investigator: Pascal MILLET, Doctor, Université Victor Segalen Bordeaux 2, Pôle des Maladies Tropicale, CHU de Bordeaux
Study Documents (Full-Text)
None provided.More Information
Publications
- Ayi K, Giribaldi G, Skorokhod A, Schwarzer E, Prendergast PT, Arese P. 16alpha-bromoepiandrosterone, an antimalarial analogue of the hormone dehydroepiandrosterone, enhances phagocytosis of ring stage parasitized erythrocytes: a novel mechanism for antimalarial activity. Antimicrob Agents Chemother. 2002 Oct;46(10):3180-4.
- Kurtis JD, Mtalib R, Onyango FK, Duffy PE. Human resistance to Plasmodium falciparum increases during puberty and is predicted by dehydroepiandrosterone sulfate levels. Infect Immun. 2001 Jan;69(1):123-8.
- Leenstra T, ter Kuile FO, Kariuki SK, Nixon CP, Oloo AJ, Kager PA, Kurtis JD. Dehydroepiandrosterone sulfate levels associated with decreased malaria parasite density and increased hemoglobin concentration in pubertal girls from western Kenya. J Infect Dis. 2003 Jul 15;188(2):297-304. Epub 2003 Jul 1.
- Libonati RM, Cunha MG, Souza JM, Santos MV, Oliveira SG, Daniel-Ribeiro CT, Carvalho LJ, do Nascimento JL. Estradiol, but not dehydroepiandrosterone, decreases parasitemia and increases the incidence of cerebral malaria and the mortality in plasmodium berghei ANKA-infected CBA mice. Neuroimmunomodulation. 2006;13(1):28-35. Epub 2006 May 12.
- Libonati RM, de Mendonça BB, Maués JA, Quaresma JA, de Souza JM. Some aspects of the behavior of the hypothalamus-pituitary-adrenal axis in patients with uncomplicated Plasmodium falciparum malaria: Cortisol and dehydroepiandrosterone levels. Acta Trop. 2006 Jul;98(3):270-6. Epub 2006 Jul 17.
- Safeukui I, Mangou F, Malvy D, Vincendeau P, Mossalayi D, Haumont G, Vatan R, Olliaro P, Millet P. Plasmodium berghei: dehydroepiandrosterone sulfate reverses chloroquino-resistance in experimental malaria infection; correlation with glucose 6-phosphate dehydrogenase and glutathione synthesis pathway. Biochem Pharmacol. 2004 Nov 15;68(10):1903-10.
- FSP 97008500